ACT is efficacious and safe for treatment of uncomplicated malaria in Tanzania.
artemisinin-based combination therapy (ACT)
Artemisinin-based combination therapy (ACT) is the recommended first-line treatment for Plasmodium falciparum malaria.
The auto-induction phase II metabolism of DHA was present in healthy Chinese subjects after the recommended two-day oral doses of DHA-PQ (Artekin).
A total of 5,990 participants were recruited and followed from day 0 to day 28.
Findings suggest vastly improved use of ACT in the retail sector after eight years of policy change, with significant contributions from AMFm drugs.
Combating counterfeit anti-malarials is a complex task due to limited resources and poor techniques for the detection and identification of fake anti-malarials.
Formative research was an important first step, and it was valuable to engage stakeholders early in the process.
Among Ugandan children, parasite clearance following treatment with AL or DP was excellent with only one of 752 patients tested having a positive blood slide three days after initiation of therapy.
An estimated 627,000 malaria deaths occurred in 2012, mostly in African children and many of them preventable with prompt diagnosis and treatment.
Increased pfmdr1 gene copy number was observed in the isolates analysed and this finding has implications for the use of ACT in the country although no resistance has been reported.